Top

Published in:

01-09-2015 | Original Article

Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats

Authors: Yanira Gonzalez, Kaytee L. Pokrzywinski, Elliot T. Rosen, Steven Mog, Baikuntha Aryal, Leena M. Chehab, Vikrant Vijay, Carrie L. Moland, Varsha G. Desai, Jennifer S. Dickey, V. Ashutosh Rao

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2015

Abstract

Purpose

Chemotherapy with doxorubicin (Dox) causes dose-limiting cardiotoxicity. We investigated the role that gender has on cardiosensitivity to Dox treatment by evaluating reproductive hormone levels in male, castrated male (c-male), female and ovariectomized female (o-female) adult spontaneously hypertensive rats (SHRs) and expression of mitochondria-related genes in male and female adult SHRs.

Methods

SST-2 breast tumor-bearing SHRs were treated with saline, Dox, dexrazoxane (Drz) or both Dox and Drz and monitored for 14 days. Tumor size was used to monitor anticancer activity. Heart weight, cardiac lesion score and serum levels of cardiac troponin T (cTnT) were used to determine cardiotoxicity. Serum estradiol (E2) and testosterone were evaluated using electrochemiluminescence immunoassays. Expression of mitochondria-related genes was profiled in heart by MitoChip array analyses.

Results

Dox significantly reduced tumor volume (±Drz) and increased heart weight in all genders (13–30 % vs. control). Higher heart lesion scores were observed in reproductively normal animals (male 2.9, female 2.2) than in hormone-deficient animals (c-male 1.7, o-female 1.9). Lesion score and cTnT inversely correlated with hormone levels. Reduced levels of both sex hormones were observed after Dox treatment. Gene expression analyses of Dox-treated hearts showed significant differential expression of oxidative stress genes in male hearts and apoptotic genes in both male and female hearts.

Conclusions

Our results demonstrate that adult tumor-bearing male SHRs are more cardiosensitive to Dox than female or hormone-deficient animals. We provide evidence to suggest that reproductive hormones negatively regulate or are inhibited by Dox-induced cardiotoxicity and the selective cytotoxic mechanism likely functions through the greater activation of oxidative stress and apoptosis in male SHRs.

Available only for authorised users

Octavia YTC, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 52:1213–1225. doi:10.1016/j.yjmcc.2012.03.006 CrossRefPubMed

Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ (2014) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1):106–135. doi:10.1002/med.21280 CrossRefPubMed

Christiansen S, Autschbach R (2006) Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg 30(4):611–616. doi:10.1016/j.ejcts.2006.06.024 CrossRefPubMed

Kumar S, Marfatia R, Tannenbaum S, Yang C, Avelar E (2012) Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Texas Heart Inst J 39(3):424–427

Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig 124(2):617–630. doi:10.1172/JCI72931 PubMedCentralCrossRefPubMed

Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS, Lele RD (2004) Free radicals and antioxidants in human health: current status and future prospects. J Assoc Phys India 52:794–804

Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49(5):330–352. doi:10.1016/j.pcad.2006.10.002 CrossRefPubMed

Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE (1987) Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 36(6):793–796CrossRefPubMed

Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Investig 65(1):128–135. doi:10.1172/JCI109642 PubMedCentralCrossRefPubMed

10.

Marklund SL, Westman NG, Lundgren E, Roos G (1982) Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res 42(5):1955–1961PubMed

11.

Ascensao A, Magalhaes J, Soares JM, Ferreira R, Neuparth MJ, Marques F, Oliveira PJ, Duarte JA (2005) Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol 289(2):H722–H731. doi:10.1152/ajpheart.01249.2004 CrossRefPubMed

12.

Kaiserova H, Simunek T, Sterba M, den Hartog GJ, Schroterova L, Popelova O, Gersl V, Kvasnickova E, Bast A (2007) New iron chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 7(2):145–150. doi:10.1007/s12012-007-0020-6 CrossRefPubMed

13.

Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, Oeffinger KC, Rosenthal DN, Sable CA, Sallan SE, Singh GK, Steinberger J, Cochran TR, Wilkinson JD, American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young CoBCSCoC, Stroke Nursing CoCR (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128(17):1927–1995. doi:10.1161/CIR.0b013e3182a88099 CrossRefPubMed

14.

Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 5(1):93–96CrossRefPubMed

15.

Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266(12):1672–1677CrossRefPubMed

16.

Dimitrova KR, DeGroot K, Myers AK, Kim YD (2002) Estrogen and homocysteine. Cardiovasc Res 53(3):577–588CrossRefPubMed

17.

Ogita H, Node K, Kitakaze M (2003) The role of estrogen and estrogen-related drugs in cardiovascular diseases. Curr Drug Metab 4(6):497–504CrossRefPubMed

18.

Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 26(19):3159–3165. doi:10.1200/JCO.2007.14.1242 CrossRefPubMed

19.

Biancaniello T, Meyer RA, Wong KY, Sager C, Kaplan S (1980) Doxorubicin cardiotoxicity in children. J Pediatr 97(1):45–50CrossRefPubMed

20.

Bell JR, Bernasochi GB, Varma U, Raaijmakers AJ, Delbridge LM (2013) Sex and sex hormones in cardiac stress—mechanistic insights. J Steroid Biochem Mol Biol 137:124–135. doi:10.1016/j.jsbmb.2013.05.015 CrossRefPubMed

21.

Zhang J, Knapton A, Lipshultz SE, Cochran TR, Hiraragi H, Herman EH (2014) Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats. Toxicol Pathol 42(2):361–375. doi:10.1177/0192623313482778 CrossRefPubMed

22.

Belham M, Kruger A, Mepham S, Faganello G, Pritchard C (2007) Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 9(4):409–414. doi:10.1016/j.ejheart.2006.09.007 CrossRefPubMed

23.

Lin DYTF, Tsai CH, Huang CY (2011) Mechanisms governing the protective effect of 17B-estradiol and estrogen receptors against cardiomyocyte injury. BioMedicine 1:21–28. doi:10.1016/j.biomed.2011.10.004 CrossRef

24.

Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA (2013) Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS ONE 8(8):e70575. doi:10.1371/journal.pone.0070575 PubMedCentralCrossRefPubMed

25.

Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54(7):1702–1706PubMed

26.

Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62(6):865–872PubMed

27.

Delongchamp R, Lee T, Velasco C (2006) A method for computing the overall statistical significance of a treatment effect among a group of genes. BMC Bioinformatics 7(Suppl 2):S11. doi:10.1186/1471-2105-7-S2-S11 PubMedCentralCrossRefPubMed

28.

Stefansky W (1972) Rejecting outliers in factorial designs. Technometrics 14:469–479CrossRef

29.

Herman EH, Zhang J, Knapton A, Lipshultz SE, Rifai N, Sistare F (2006) Serum cardiac troponin as a biomarker for acute myocardial injury induced by low doses of isoproterenol in rats. Cardiovasc Toxicol 6:211–221CrossRefPubMed

30.

Andersson H, Rehm S, Stanislaus D, Wood CE (2013) Scientific and regulatory policy committee (SRPC) paper: assessment of circulating hormones in nonclinical toxicity studies III. Female reproductive hormones. Toxicol Pathol 41(6):921–934. doi:10.1177/0192623312466959 CrossRefPubMed

31.

Julicher RH, Sterrenberg L, Haenen GR, Bast A, Noordhoek J (1988) The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch Toxicol 61(4):275–281CrossRefPubMed

32.

Godoy LY, Fukushige J, Igarashi H, Matsuzaki A, Ueda K (1997) Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 39(2):188–193CrossRefPubMed

33.

Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22(10):1864–1871. doi:10.1200/JCO.2004.06.033 CrossRefPubMed

34.

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26(22):3777–3784. doi:10.1200/JCO.2007.14.9401 PubMedCentralCrossRefPubMed

35.

Munoz-Castaneda JR, Muntane J, Herencia C, Munoz MC, Bujalance I, Montilla P, Tunez I (2006) Ovariectomy exacerbates oxidative stress and cardiopathy induced by adriamycin. Gynecol Endocrinol 22(2):74–79. doi:10.1080/09513590500490249 CrossRefPubMed

36.

Deschamps AM, Murphy E (2009) Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297(5):H1806–H1813. doi:10.1152/ajpheart.00283.2009 PubMedCentralCrossRefPubMed

37.

Patten RD, Karas RH (2006) Estrogen replacement and cardiomyocyte protection. Trends Cardiovasc Med 16(3):69–75. doi:10.1016/j.tcm.2006.01.002 CrossRefPubMed

38.

Wang M, Tsai BM, Kher A, Baker LB, Wairiuko GM, Meldrum DR (2005) Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. Am J Physiol Heart Circ Physiol 288(1):H221–H226. doi:10.1152/ajpheart.00784.2004 CrossRefPubMed

39.

Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P (1995) Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91(4):1154–1160CrossRefPubMed

40.

Zaugg M, Jamali NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, Siddiqui MA (2001) Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol 187(1):90–95. doi:10.1002/1097-4652(2001)9999:9999<00:AID-JCP1057>3.0.CO;2-Y CrossRefPubMed

41.

Welder AA, Robertson JW, Fugate RD, Melchert RB (1995) Anabolic-androgenic steroid-induced toxicity in primary neonatal rat myocardial cell cultures. Toxicol Appl Pharmacol 133(2):328–342. doi:10.1006/taap.1995.1158 CrossRefPubMed

42.

Curl CL, Wendt IR, Kotsanas G (2001) Effects of gender on intracellular. Pflugers Arch 441(5):709–716CrossRefPubMed

43.

Altamirano F, Oyarce C, Silva P, Toyos M, Wilson C, Lavandero S, Uhlen P, Estrada M (2009) Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J Endocrinol 202(2):299–307. doi:10.1677/JOE-09-0044 CrossRefPubMed

44.

Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH (2004) 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 95(7):692–699. doi:10.1161/01.RES.0000144126.57786.89 CrossRefPubMed

Title: Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats
Authors: Yanira Gonzalez
Kaytee L. Pokrzywinski
Elliot T. Rosen
Steven Mog
Baikuntha Aryal
Leena M. Chehab
Vikrant Vijay
Carrie L. Moland
Varsha G. Desai
Jennifer S. Dickey
V. Ashutosh Rao
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2786-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2015

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors

S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612)

RETRACTED ARTICLE: ABCB1 (1199G>A) polymorphism regulates the efficacy of docetaxel and imatinib mesylate in HEK293 recombinant cell lines

Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer